Clinical Trial

PCSK9 Inhibitors in the Treatment of Calcific Aortic Stenosis

Study acronym: PICASO
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Calcific aortic stenosis (CAS) can cause severe adverse cardiac events, but there are currently no effective drugs that can prevent or delay the progression of the disease. Our trial aims to investigate the effect of PCSK9 inhibitors on preventing or delaying the progression of CAS.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-11-20; most recent amendment 2026-03-29.
Trial Details
NCT Number NCT07256197
Lead Sponsor Beijing Anzhen Hospital
Collaborators: Beijing Jishuitan Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital, Beijing Hospital, Nanchong Central Hospital, Peking University First Hospital, Beijing Luhe Hospital
Conditions Aortic Stenosis, Calcific
Enrollment 160 participants
Start Date 2026-04-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-02